21 results
10-Q
2021 Q2
RNAZ
TransCode Therapeutics Inc
23 Aug 21
Quarterly report
4:53pm
are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product
DRS
RNAZ
TransCode Therapeutics Inc
29 Jul 22
Draft registration statement
12:00am
success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition
10-K
2021 FY
RNAZ
TransCode Therapeutics Inc
31 Mar 22
Annual report
11:19am
in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from
DRS/A
od46uuqnco 56p
27 Jan 21
Draft registration statement (amended)
12:00am
DRS
gardwnv7emtmw8phbm
18 Dec 20
Draft registration statement
12:00am
424B4
ayeelxj4
19 Jan 24
Prospectus supplement with pricing info
9:57pm
424B4
lecav7e1543fzf9h 2p
9 Jul 21
Prospectus supplement with pricing info
5:22pm